Aram F Hezel

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/12009610/publications.pdf

Version: 2024-02-01

37 papers	8,393 citations	230014 27 h-index	388640 36 g-index
40 all docs	40 docs citations	40 times ranked	14182 citing authors

#	Article	IF	Citations
1	GM-CSF drives myelopoiesis, recruitment and polarisation of tumour-associated macrophages in cholangiocarcinoma and systemic blockade facilitates antitumour immunity. Gut, 2022, 71, 1386-1398.	6.1	28
2	FOSL1 promotes cholangiocarcinoma via transcriptional effectors that could be therapeutically targeted. Journal of Hepatology, 2021, 75, 363-376.	1.8	29
3	Endocrine-Exocrine Signaling Drives Obesity-Associated Pancreatic Ductal Adenocarcinoma. Cell, 2020, 181, 832-847.e18.	13.5	77
4	Kras and Tp53 Mutations Cause Cholangiocyte- and Hepatocyte-Derived Cholangiocarcinoma. Cancer Research, 2018, 78, 4445-4451.	0.4	79
5	Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma. Cancer Discovery, 2016, 6, 727-739.	7.7	126
6	Intra-pancreatic Distal Bile Duct Carcinoma is Morphologically, Genetically, and Clinically Distinct from Pancreatic Ductal Adenocarcinoma. Journal of Gastrointestinal Surgery, 2016, 20, 953-959.	0.9	12
7	Combined MEK and PI3K Inhibition in a Mouse Model of Pancreatic Cancer. Clinical Cancer Research, 2015, 21, 396-404.	3.2	121
8	Genetics and Biology of Pancreatic Ductal Adenocarcinoma. Hematology/Oncology Clinics of North America, 2015, 29, 595-608.	0.9	58
9	Mutant IDH inhibits HNF-4Î± to block hepatocyte differentiation and promote biliary cancer. Nature, 2014, 513, 110-114.	13.7	367
10	Plac8 Links Oncogenic Mutations to Regulation of Autophagy and Is Critical to Pancreatic Cancer Progression. Cell Reports, 2014, 7, 1143-1155.	2.9	69
11	New and emerging treatment options for biliary tract cancer. OncoTargets and Therapy, 2013, 6, 1545.	1.0	17
12	TGF-Î² and Î±vÎ²6 Integrin Act in a Common Pathway to Suppress Pancreatic Cancer Progression. Cancer Research, 2012, 72, 4840-4845.	0.4	82
13	KrasG12D and p53 Mutation Cause Primary Intrahepatic Cholangiocarcinoma. Cancer Research, 2012, 72, 1557-1567.	0.4	405
14	Frequent Mutation of Isocitrate Dehydrogenase (IDH)1 and IDH2 in Cholangiocarcinoma Identified Through Broad-Based Tumor Genotyping. Oncologist, 2012, 17, 72-79.	1.9	629
15	Oncogenic Kras Maintains Pancreatic Tumors through Regulation of Anabolic Glucose Metabolism. Cell, 2012, 149, 656-670.	13.5	1,587
16	A phase I study of temsirolimus in combination with gemcitabine in previously untreated metastatic pancreatic cancer.. Journal of Clinical Oncology, 2012, 30, 296-296.	0.8	2
17	Mutational profiling reveals PIK3CA mutations in gallbladder carcinoma. BMC Cancer, 2011, 11, 60.	1.1	83
18	Development of molecularly targeted therapies in biliary tract cancers: Reassessing the challenges and opportunities. Hepatology, 2011, 53, 695-704.	3.6	62

#	Article	IF	Citations
19	PTEN Is a Major Tumor Suppressor in Pancreatic Ductal Adenocarcinoma and Regulates an NF-Î²Bâ€“Cytokine Network. Cancer Discovery, 2011, 1, 158-169.	7.7	186
20	Genetically Engineered Mouse Models of Pancreatic Ductal Adenocarcinoma. , 2011, , 377-395.		0
21	Current Management of Gallbladder Carcinoma. Oncologist, 2010, 15, 168-181.	1.9	279
22	Genetics of Biliary Tract Cancers and Emerging Targeted Therapies. Journal of Clinical Oncology, 2010, 28, 3531-3540.	0.8	185
23	Oral mTOR Inhibitor Everolimus in Patients With Gemcitabine-Refractory Metastatic Pancreatic Cancer. Journal of Clinical Oncology, 2009, 27, 193-198.	0.8	275
24	Inhibition of Î³-Secretase Activity Inhibits Tumor Progression in a Mouse Model of Pancreatic Ductal Adenocarcinoma. Gastroenterology, 2009, 136, 1741-1749.e6.	0.6	155
25	Prognostic markers in pancreatic ductal adenocarcinomas. Cancer Biology and Therapy, 2008, 7, 1360-1361.	1.5	5
26	Pancreatic Lkb1 Deletion Leads to Acinar Polarity Defects and Cystic Neoplasms. Molecular and Cellular Biology, 2008, 28, 2414-2425.	1.1	137
27	Genomic alterations link Rho family of GTPases to the highly invasive phenotype of pancreas cancer. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 19372-19377.	3.3	134
28	Systemic Therapy for Biliary Tract Cancers. Oncologist, 2008, 13, 415-423.	1.9	195
29	LKB1 Deficiency Sensitizes Mice to Carcinogen-Induced Tumorigenesis. Cancer Research, 2008, 68, 55-63.	0.4	81
30	Emerging therapies for colorectal cancer. Expert Opinion on Investigational Drugs, 2007, 16, 867-876.	1.9	4
31	Stromal biology of pancreatic cancer. Journal of Cellular Biochemistry, 2007, 101, 887-907.	1.2	290
32	Both p16Ink4a and the p19Arf-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 5947-5952.	3.3	537
33	Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer. Genes and Development, 2006, 20, 3130-3146.	2.7	562
34	Genetics and biology of pancreatic ductal adenocarcinoma. Genes and Development, 2006, 20, 1218-1249.	2.7	1,118
35	Telomere Induced Senescence: End Game Signaling. Current Molecular Medicine, 2005, 5, 145-152.	0.6	12
36	Loss of the Lkb1 tumour suppressor provokes intestinal polyposis but resistance to transformation. Nature, 2002, 419, 162-167.	13.7	390

#	Article	IF	Citations
37	Models of intrahepatic cholangiocarcinoma: novel tools and therapeutic applications. Gastrointestinal Cancer: Targets and Therapy, 0, Volume 8, 1-11.	5.5	1